IP Library Granted Patent US 10,314,743
Granted Patent B2
US 10,314,743 · App. 15/454,945 · Granted Jun 11, 2019

Intraocular shunt manufacture

Inventors: Laszlo O. Romoda (San Clemente, CA); Brian Hamstrom (Trabuco Canyon, CA); Partha Chandrakant (Foothill Ranch, CA); Christopher Horvath (Mission Viejo, CA)
Assignee: AQUESYS, INC.
A61F9/00781A61F9/0017B05C3/12C23C2/00A61F2240/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,743
App. No.
15/454,945
Granted
Jun 11, 2019
Kind
B2
Abstract

An intraocular shunt can be manufactured using a system that includes a liquid bath and a wire, which is moved through the bath. The wire can be moved through a first liquid bath to produce a first tubular layer of drug-infused gelatin. Further, the wire can be moved through a second liquid bath to produce a second tubular layer of drug-free gelatin. The first and second tubular layers can be dried on the wire in a humidity-controlled space, thereby manufacturing a drug-loaded gelatin shunt.

Claims (25)

1. A method for manufacturing a gelatin shunt, the method comprising:

moving a wire through a first liquid bath to produce a first tubular layer of drug-infused gelatin;

moving the wire through a second liquid bath to produce a second tubular layer of drug-free gelatin; and

while exposing the gelatin coating to an ultrasonic water fog, drying the first and second tubular layers on the wire in a humidity-controlled space, thereby manufacturing a drug-loaded gelatin shunt.

2. The method of claim 1 , wherein the first tubular layer ranges between 3 μm and 20 μm in thickness.

3. The method of claim 1 , wherein the moving the wire through the first liquid bath is performed after moving the wire through the second liquid bath.

4. The method of claim 1 , wherein the wire comprises a drug-free gelatin layer, and moving the wire through the first liquid bath comprises soaking the drug into the drug-free gelatin layer to produce the first tubular layer of drug-infused gelatin.

5. The method of claim 1 , further comprising cross-linking the first tubular layer.

6. The method of claim 5 , wherein the cross-linking the first tubular layer occurs before the moving the wire through the second liquid bath.

7. The method of claim 1 , further comprising cross-linking the second tubular layer.

8. The method of claim 7 , wherein the cross-linking the second tubular layer occurs before the moving the wire through the first liquid bath.

9. The method of claim 1 , wherein the first liquid bath is infused with a drug.

10. The method of claim 1 , wherein the moving the wire through the first liquid bath comprises moving the wire through a drug-free liquid bath to produce a preformed layer and thereafter soaking the preformed layer in a drug to produce the first tubular layer.

11. The method of claim 1 , wherein the drug is selected from the group consisting of an anti-mitotic pharmaceutical, an anti-VEGF agent, a steroid, an antifibrotic agent, an antimicrobial agent, an antiseptic, and a time-release pharmaceutical or biological agent.

12. The method of claim 1 , wherein the drying the first and second tubular layers comprises drying the first tubular layer before the moving the wire through the second liquid bath.

13. A method for manufacturing a gelatin shunt, the method comprising:

moving a wire through a liquid bath to coat the wire with gelatin, thereby producing a gelatin-coated wire comprising a gelatin coating;

while exposing the gelatin coating to an ultrasonic water fog, drying the gelatin coating on the wire in a humidity-controlled space, thereby manufacturing a gelatin shunt; and coating the gelatin shunt with a drug.

14. The method of claim 13 , further comprising:

drawing the gelatin-coated wire through an aperture before drying the gelatin coating, thereby controlling a cross-sectional thickness of the gelatin coating.

15. The method of claim 14 , further comprising:

cross-linking the gelatin coating after coating the gelatin shunt with the drug.

16. The method of claim 14 , wherein the drug is selected from the group consisting of an anti-mitotic pharmaceutical, an anti-VEGF agent, a steroid, an antifibrotic agent, an antimicrobial agent, an antiseptic, and a time-release pharmaceutical or biological agent.

17. The method of claim 14 , wherein coating the gelatin shunt comprises coating an exterior surface of the gelatin shunt with the drug.

18. The method of claim 14 , wherein the liquid bath comprises a top layer and a bottom layer, the top layer comprising water and the bottom layer comprising gelatin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: HORVATH, CHRISTOPHER; ROMODA, LASZLO O.; HAMSTROM, BRIAN; CHANDRAKANT, PARTHA
To: AQUESYS, INC.
Reel/Frame 061411/0202 →
Continuity (4)
Continuation 14834158 · Aug 24, 2015
Continuation 14295020 · Jun 3, 2014
Continuation 13314950 · Dec 8, 2011
Related Publication 20170172800A1 · Jun 22, 2017
Cited By (12)
US 12,220,350 US 12,226,343 US 12,329,682 US 12,370,085 US 12,447,046 US 12,453,657 US 12,472,097 US 12,472,098 US 12,539,404 US 12,551,268 US 12,667,488 US 12,678,328